Overview

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Status:
Completed
Trial end date:
2018-03-21
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate and compare the plasma pharmacokinetic profiles of ACH-0144471 (danicopan) in healthy participants after administration of single oral doses of modified release prototype formulations.
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharmaceuticals
Collaborator:
Achillion, a wholly owned subsidiary of Alexion